SENORES PHARMACEUTICALS LIMITE (SENORES)

Current Price: ₹0.00

Back to Home
Stock Performance

Quarterly Financials

Consolidated Standalone
Particulars Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 103.02 114.21 137.99 161.76 174.56 175.19
YOY Revenue Growth % - - - - 69.45% 53.39%
Other Income 5.16 11.77 3.36 5.41 3.78 17.67
Total Income 108.17 125.98 141.35 167.17 178.34 192.86
Total Expenses + 59.74 105.30 114.86 126.53 133.74 145.46
Cost of Materials Consumed 23.10 20.94 29.38 46.09 36.96 27.05
Employee Benefit Expense 19.01 14.63 21.65 29.62 30.66 30.32
Other Expenses 17.63 22.68 20.81 25.55 22.88 31.16
Operating Profit 43.28 8.91 23.13 35.23 40.82 29.73
OPM % 42% 7.8% 16.8% 21.8% 23.4% 17%
Profit Before Tax + 20.48 20.68 26.49 40.64 44.60 47.40
Tax Expense 4.05 2.71 5.31 10.52 11.02 10.73
Tax % 19.8% 13.1% 20% 25.9% 24.7% 22.6%
Profit After Tax 16.43 17.97 21.18 30.12 33.58 36.67
EPS (Basic) 5.04 3.81 4.60 6.54 7.29 7.96

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2025
Revenue from Operations 398.25
YOY Revenue Growth % -
Other Income 19.26
Total Income 417.51
Total Expenses + 346.94
Cost of Materials Consumed 91.64
Employee Benefit Expense 60.37
Other Expenses 67.48
Operating Profit 51.31
OPM % 12.9%
Profit Before Exceptional 70.57
Exceptional Items 0.00
Profit Before Tax + 70.57
Tax Expense 12.23
Tax % 17.3%
Profit After Tax 58.34
EPS (Basic) 16.12

Balance Sheet

Particulars Mar 2025
ASSETS
Non-Current Assets + 504.43
Property, Plant & Equipment 198.85
Capital Work in Progress 44.17
Non-Current Investments 0.01
Goodwill 38.21
Other Intangible Assets 54.27
Current Assets + 722.43
Inventories 56.63
Trade Receivables 123.88
Cash and Cash Equivalents 105.38
Current Investments 0.00
LIABILITIES & EQUITY
Total Equity 0.00
Equity Share Capital 46.05
Other Equity 740.13
Non-Current Liabilities 173.92
Current Liabilities 240.70
Total Liabilities 414.62

Cash Flow Statement

Particulars Mar 2025
Cash from Operating Activities -45.92
Cash from Investing Activities -429.48
Cash from Financing Activities 573.14
Net Increase/Decrease in Cash 97.74